DiaMedica Therapeutics (DMAC) Proxy Filing summary

Executive summary

• The annual general meeting is scheduled for May 15, 2025, with shareholders voting on director elections, auditor appointment, and executive compensation approval.

• Shareholders of record as of March 18, 2025, are eligible to vote, with materials available online to reduce costs and environmental impact.

• The board recommends voting in favor of all proposals and provides multiple voting methods, including online, phone, and mail.

Voting matters and shareholder proposals

• Seven directors are up for election for one-year terms; all are current board members.

• Appointment of Baker Tilly US, LLP as independent auditor for 2025 and authorization for the board to set remuneration.

• Advisory (non-binding) vote on executive compensation (say-on-pay), with the next say-on-pay vote scheduled for 2026.

• Shareholder proposals for the 2026 meeting must be submitted by November 28, 2025.

Board of directors and corporate governance

• Board consists of a majority of independent directors, with an independent chairman and four fully independent committees.

• Recent board refreshment and leadership rotation, with three new directors added in the past two years.

• Board diversity includes 14% women and 29% racially or ethnically diverse members; average independent director tenure is 6.3 years.

• Committees include Audit, Compensation, Nominating and Corporate Governance, and Scientific and Clinical Research.

• Directors are encouraged to attend annual meetings; all attended in 2024.